Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News
11:09am, Friday, 24'th Feb 2023
There's no doubt Fulcrum Therapeutics (NASDAQ: FULC ) is committed to advancing its proposed treatment for sickle cell disease. However, there's a regulatory holdup.
Are You Looking for a Top Momentum Pick? Why Fulcrum Therapeutics, Inc. (FULC) is a Great Choice
01:32pm, Wednesday, 01'st Feb 2023
Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?
09:02am, Wednesday, 11'th Jan 2023
Fulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further st
Fulcrum Therapeutics, Inc. (FULC) Q3 2022 Earnings Call Transcript
02:58pm, Saturday, 12'th Nov 2022
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2022 Results Conference Call November 8, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern Investor Relations Bryan Stuart - President and Chie
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
07:05am, Wednesday, 02'nd Nov 2022
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
05:29pm, Tuesday, 01'st Nov 2022
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Here's Why Fulcrum Therapeutics, Inc. (FULC) is Poised for a Turnaround After Losing 32.6% in 4 Weeks
11:18am, Friday, 21'st Oct 2022
Fulcrum Therapeutics, Inc. (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana
- 96-week findings support losmapimod as a disease-modifying therapy for FSHD
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
04:01pm, Tuesday, 06'th Sep 2022
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with geneticall
Fulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2022 Results - Earnings Call Transcript
01:18pm, Thursday, 11'th Aug 2022
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern, Investor Relations Bryan Stuart - President & Chief
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Thursday, 11'th Aug 2022
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -25.76% and 28.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
02:24pm, Monday, 27'th Jun 2022
Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues.
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development
Fulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call Transcript
10:54am, Monday, 09'th May 2022
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan Stuart - President & CEO Ju
